Orbimed Advisors bought $10M worth of QTTB at $8.00, increasing its stake by 55.5% and entering at a price 39.2% below the 90-day high. This represents a dramatic reversal from their previous selling pattern of $13.4M over four transactions, signaling a strong conviction that the selloff is overdone. Bull: breaks above $9.50 → targets $11.50+. Bear: breaks below $7.20 support.

Where it could go — No historical pattern data for QTTB; broad base rate 0% positive at 90d. Bull holds $7.20, bear breaks $6.80.

Orbimed Advisors bought $10M worth of QTTB at $8.00, increasing its stake by 55.5% and entering at a price 39.2% below the 90-day high. This represents a dramatic reversal from their previous selling pattern of $13.4M over four transactions, signaling a strong conviction that the selloff is overdone. Bull: breaks above $9.50 → targets $11.50+. Bear: breaks below $7.20 support.

Where it could go — No historical pattern data for QTTB; broad base rate 0% positive at 90d. Bull holds $7.20, bear breaks $6.80.

Director Xu Diyong bought $10.0M worth of QTTB at $8.00 per share, increasing his stake by 55.5% and entering at a price 39.2% below the 90-day high. This first-time purchase by a director with no prior trading history suggests strong belief in the company's value proposition despite the stock's recent weakness. Bull: maintains STRONG BUY analyst consensus → targets near $13. Bear: breaks below $4.97 recent low.

Where it could go — Broad base rate 0.0% positive at 90d; bull holds $4.97, bear breaks $4.17.